Gilead Sciences Inc
NASDAQ: GILD
$83.94
+$0.04 (+0.0%)
Closing Price on September 20, 2024
GILD Articles
The July 31 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
Published:
Last Updated:
After a wretched 2016, when many of the top biotech companies were hit hard by campaign rhetoric, the industry has roared back to life this year. Here are four big opportunities for aggressive...
Published:
Last Updated:
The July 14 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
Published:
Last Updated:
Gilead Sciences, Inc. (NASDAQ: GILD) shares basically remained unchanged after the firm announced an approval from the U.S. Food and Drug Administration (FDA). Essentially, the FDA approved Vosevi...
Published:
Last Updated:
The June 30 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
Published:
Last Updated:
The biotech industry has made a splash in 2017, outperforming practically all the broad markets. With this incredible display, it's no wonder that investor interest in this particular industry has...
Published:
Last Updated:
Many on Wall Street feel that some of the more speculative institutional tech money may be rotating into the biotechs, and with good reason.
Published:
Last Updated:
The June 15 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Friday include AK Steel, Altice USA, Biogen, Caterpillar, Gilead Sciences and Oracle.
Published:
Last Updated:
The May 31 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
Published:
Last Updated:
The May 15 short interest data have been compared with the previous report, and moves in the selected biotech stocks were mixed.
Published:
Last Updated:
With prescription drug spending breaking new records almost every year now, people like to blame Big Pharma and use it as the industry punching bag.
Published:
Last Updated:
The April 28 short interest data have been compared with the previous report, and moves in the selected biotech stocks were mixed.
Published:
Last Updated:
Many value investors have flocked to Gilead Sciences as the world's top biotech stock now that it is valued at a lower multiple than Big Pharma rivals.
Published:
Last Updated:
As of the start of May of 2017, just 21 members of the S&P 500 Index were valued at less than 10 times expected earnings per share.
Published:
Last Updated: